The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (ILD), acute and/or severe (may cause ARDS)
Publications
Buxhofer-Ausch V, Ruckser R, Kier P, Habertheuer KH, Zelenka P, Tatzreiter G, Ausch C, Schmid I, Hruby W, Reiner-Concin A, Sebesta C, Ogris E, Hinterberger-Fischer M, Hinterberger W
A rare case of interstitial pneumonitis after tandem high-dose melphalan conditioning and autologous stem cell transplantation in multiple myeloma.
European journal of haematology 2004 Aug;73;143-6 — 2004 Aug — 143-6
Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation.
Bone marrow transplantation 2000 Nov;26;1107-9 — 2000 Nov — 1107-9
Reversible melphalan-induced lung damage.
The American journal of medicine 1980 May;68;767-71 — 1980 May — 767-71